The Need for Psychosocial Interventions to Facilitate the Transition to Extended-Release Naltrexone (XR-NTX) Treatment for Opioid Dependence: A Concise Review of the Literature.
The Need for Psychosocial Interventions to Facilitate the Transition to Extended-Release Naltrexone (XR-NTX) Treatment for Opioid Dependence: A Concise Review of the Literature.
复制标题
DOI：
10.4137/sart.s39067
复制
发表时间：
2016
期刊：
影响因子：
--
通讯作者：
Friedmann P
中科院分区：
文献类型：
--
作者：
Ramsey SE;Rounsaville D;Hoskinson R;Park TW;Ames EG;Neirinckx VD;Friedmann P
鉴于类阿片依赖和类阿片相关发病率和死亡率的增加，改进类阿片依赖者的治疗选择值得更多关注。本文简要回顾了这方面的工作。阿片类药物依赖的缓解可能很难持续，特别是在没有阿片类药物替代或阿片类药物拮抗剂治疗的情况下。对于希望从阿片类药物使用或阿片类药物替代治疗过渡到阿片类药物拮抗剂治疗的患者，一个重大挑战可能是在开始阿片类药物拮抗剂治疗之前必须忍受的戒断症状期。将社会心理干预纳入戒毒方案的研究发现，这些干预措施可改善治疗效果。基于接受和承诺疗法的干预措施在治疗临床疾病方面表现出了希望，这些疾病的症状与阿片类药物戒断症状相似，并且已发现对美沙酮逐渐减少的患者产生积极影响。然而，在过渡到XR-NTX的阿片类药物依赖患者中使用基于接受和承诺疗法的干预措施尚未进行研究，其对过渡到XR-NTX的患者的价值目前尚不清楚。
Given the increase of opioid dependence and opioid-related morbidity and mortality, improving treatment options for individuals with opioid dependence warrants increased attention. This article provides a concise review of work in this area. Remission from opioid dependence can be very difficult to sustain, particularly in the absence of opioid replacement or opioid antagonist therapy. For those who wish to transition from opioid use or opioid replacement therapy to opioid antagonist therapy, a significant challenge can be the period of withdrawal symptoms that must be endured prior to the initiation of opioid antagonist therapy. Studies that have incorporated psychosocial interventions into detoxification protocols have found that they can result in improved treatment outcomes. Interventions based on Acceptance and Commitment Therapy have shown promise in the treatment of clinical disorders that present with symptoms similar to those of opioid withdrawal and have been found to positively impact outcomes among those tapering from methadone. However, the use of an Acceptance and Commitment Therapy-based intervention has yet to be studied among opioid-dependent patients transitioning to XR-NTX, and its value to those transitioning to XR-NTX is currently unknown.